Payment overview · 2025
General Payments
$174.26
10 reported records · 8 companies
Healthcare provider profile · identity verified
Bridgett D Wilson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GILBERT, AZ · NPI 1255443313
Verified facts
What the public records show
CMS Open Payments records show Bridgett D Wilson, M.D. received $174.26 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.97 | 18.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.88 | 17.7% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.57 | 12.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.54 | 11.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.34 | 10.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.22 | 10.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.65 | 9.6% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $15.09 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.26 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 602 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 105 |
| Losartan Potassium | Losartan Potassium | 267 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 69 |
| Lisinopril | Lisinopril | 249 | 70 |
| Simvastatin | Simvastatin | 213 | 58 |
| Metformin Hcl | Metformin Hcl | 205 | 58 |
| Omeprazole | Omeprazole | 178 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 40 |
| Trazodone Hcl | Trazodone Hcl | 113 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 29 |
| Bupropion Xl | Bupropion Hcl | 99 | 25 |
| Alendronate Sodium | Alendronate Sodium | 98 | 24 |
| Sertraline Hcl | Sertraline Hcl | 98 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 26 |
| Gabapentin | Gabapentin | 82 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 23 |
| Lovastatin | Lovastatin | 65 | 19 |
| Synthroid | Levothyroxine Sodium | 56 | 12 |
| Allopurinol | Allopurinol | 53 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Alprazolam | Alprazolam | 37 | 12 |
| Atenolol | Atenolol | 36 | suppressed |
| Furosemide | Furosemide | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 18 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Eliquis | Apixaban | 30 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Ozempic | Semaglutide | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Famotidine | Famotidine | 27 | 11 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.26 · 10 records | Amgen Inc. | Cologuard Collection Kit, Da Vinci Surgical System, EVENITY, FARXIGA, KRYSTEXXA, NURTEC ODT, QULIPTA, SYNTHROID, Tymlos, UBRELVY, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error